Related content

Feasibility study of S-1 adjuvant chemotherapy in patients with colorectal cancer

By Ogawa Masaichi   Watanabe Michiaki   Kobayashi Tetsuya   Eto Ken   Oda Akihiro   Anan Tadashi   Hayashi Takenori   Mitsuyama Yoshinobu   Yanaga Katsuhiko  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 678-683

Springer Publishing Company

Access to resources Recommend Favorite

Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1

By Aoyama Toru  

Gastric Cancer, Vol. 14, Iss. 2, 2011-06 ,pp. : 150-154

Springer Publishing Company

Access to resources Recommend Favorite

Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1451-1457

Spandidos Publications

Access to resources Recommend Favorite

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients

By Sakata Y.   Ohtsu A.   Horikoshi N.   Sugimachi K.   Mitachi Y.   Taguchi T.  

European Journal of Cancer, Vol. 34, Iss. 11, 1998-10 ,pp. : 1715-1720

Elsevier

Access to resources Recommend Favorite

Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest

By                                        

Molecular and Clinical Oncology, Vol. 3, Iss. 3, 2015-01 ,pp. : 527-532

Science Publishers

Access to resources Recommend Favorite